Third Peoples Hospital of Jingzhou
Third Peoples Hospital of Jingzhou
Yang L.,Wuhan University |
Yang L.,Third Peoples Hospital of Jingzhou |
Liu J.-J.,Third Peoples Hospital of Jingzhou
Chinese Journal of Schistosomiasis Control | Year: 2013
Objective: To study the feasibility and effect of clinical nursing path in the standard management of advanced schistosomiasis patients with splenomegaly. Methods: A total of 64 advanced schistosomiasis patients with splenomegaly were randomly divided into a routine nursing group (control group) and a clinical nursing pathway group (CNP group), and the postoperative situation, average hospitalization days, cost of hospitalization and the satisfaction of the patients of the 2 groups were compared. Results: The complications, average hospitalization days, costs of hospitalization in the CNP group were significantly decreased compared with those in the control group, and satisfaction rate of the patients in the CNP group increased from 81.25% to 100%. Conclusion: The implementation of CNP effectively reduces the length of hospitalization, costs and complications, and improves the satisfaction of the patients.
Huo Y.,Wuhan Institute of Biological Products Co. |
Cai A.,Third Peoples Hospital of Jingzhou |
Yang H.,Third Peoples Hospital of Jingzhou |
Zhou M.,Third Peoples Hospital of Jingzhou |
And 3 more authors.
Virus Genes | Year: 2014
A newly emerged pandemic Sydney GII.4-like norovirus (NoV) (Jingzhou GII.4) was isolated in Jingzhou, China in April, 2013, demonstrating the rapid spread of the variant to China. The complete nucleotide sequence was compared with the prototype Sydney 2012 variant and its VP1 gene with that of Huzhou strain (isolated in January 2013 in Huzhou, China). The result demonstrates that the new variant has evolved rapidly, including mutations in the hypervariable P2 domain of the major capsid protein VP1. Our study also shows that the new Jingzhou GII.4 variant co-circulated with GII.3 and GI.2 at the same time, supporting further monitoring of the evolution of the new NoV variant in China. © 2013 Springer Science+Business Media New York.
Chen D.-Q.,Third Peoples Hospital of Jingzhou |
Cai A.-L.,Third Peoples Hospital of Jingzhou |
Zhou M.-L.,Third Peoples Hospital of Jingzhou |
Yang H.,Third Peoples Hospital of Jingzhou
Chinese Journal of Biologicals | Year: 2014
Objective: To express the capid protein of Norovirus (NoVs) in 293T cells and purify the expressed product. Methods: The VP1 gene sequence of NoVs GII. 4 strain causing pandemic in Sydney, at a length of 1 623 bp, was synthesized and inserted into vector pcDNA3. 1(+). The constructed recombinant plasmid was identified by sequencing and transfected to 293T cells by co-precipitation with calcium phosphate. The supernatant of cells was harvested 3-5 d after transfection, from which capid protein was purified by density gradient centrifugation with cesium chloride. Various components were collected, from which virus-like particles (VLPs) were precipitated by centrifugation, re-suspended by PBS, analyzed for purity by SDS-PAGE, observed by electron microscopy, and determined for protein content by BCA method. Results: The culture supernatant of 293T cells transfected with constructed recombinant plasmid showed specific protein bands on Western blot profile. However, the harvested culture supernatant after density gradient centrifugation with cesium chloride showed three obvious bands. The 10% SDS-PAGE showed that the capsid protein was mainly located in the third band, with a purity of more than 95%. The target protein showed two bands with relative molecular masses of 59 000 and 56 000 respectively. Electron microscopy showed that the expressed capid protein was mainly located in the third band and was assembled to VLPs at sizes of about 30 nm. About 500 μg VLPs were obtained from each liter of medium. Conclusion: The capsid protein of NoVs was successfully expressed in 293T cells and assembled into VLPs. A novel method for small scale production of VLPs of NoVs was developed in this paper.